av/poxel-sa--big.svg

COM:POXELPHARMA

Poxel SA

  • Stock

Last Close

0.27

12/11 16:35

Market Cap

22.74M

Beta: -

Volume Today

127.25K

Avg: -

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pa...Show More

peer of

investor of

competitor of